Current Headlines

  1. Molecular Devices Partners With Roche To Develop Custom Ruthenium Nano-TRF® Detection Platform

    The custom technologies arm of Molecular Devices, a leader in bioanalytical systems for drug discovery, life science research, and bioassay development, has partnered with the Discovery Technologies team at the Roche Innovation Center Basel of Pharma Research and Early Development (pRED) to develop a high-throughput detection system for drug discovery screens employing Roche's proprietary Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF®) assays

  2. Ironwood Pharmaceuticals Initiates Phase III Trial Of 72 mcg Linaclotide In Adult Patients With Chronic Idiopathic Constipation

    Ironwood Pharmaceuticals, Inc. announced recently the initiation of a Phase III clinical trial in the U.S. evaluating a 72 mcg capsule of linaclotide to be taken once per day for the treatment of adults suffering from chronic idiopathic constipation (CIC)

  3. Zilver PTX Drug-Eluting Stent Study Data Show Continued Patency At Five Years

    Five-year results from the largest and longest-running clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) confirmed long-term patency for patients treated with Zilver PTX

  4. Medidata And PPD Partner To Offer New Approach To Risk-Based Monitoring

    Medidata, a leading global provider of cloud-based solutions for clinical research in life sciences, and Pharmaceutical Product Development, LLC (PPD), a global contract research organization (CRO), recently announced they are expanding their partnership to provide the life science industry with a more comprehensive approach to risk-based monitoring (RBM)—aimed at conducting drug development more intelligently, more quickly and more cost-effectively

  5. Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease

    Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, recently announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease

  6. Dyax Corp. Announces Expansion Of Phase 1b Clinical Trial For DX-2930

    Dyax Corp. recently announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts

  7. PTC Therapeutics Expands Access For Translarna™ (Ataluren)

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been approved to be included in the list of drugs reimbursable by the Italian National Health System under Law 648/96

  8. New Research In Pharmacologic Decision-Making In The Treatment Of Focal Epilepsy— A Critical Comparison Of Antiepileptic Drugs

    Physicians who treat patients with epilepsy must balance many factors when selecting the appropriate treatment for an individual patient, including seizure type, concomitant antiepileptic drug (AED) therapy, age, comorbid conditions, and even insurance coverage

  9. Capsugel Advances The First Intrinsically Enteric Capsule Technology

    Capsugel announced today the expansion of its lead-user customer-collaboration program for its intrinsically enteric capsule technology

  10. RetroSense Therapeutics Granted Orphan Drug Designation For Lead Product RST-001 For Retinitis Pigmentosa

    RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced recently that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP)

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.